Mayne Pharma Group Limited (ASX: MYX)
Health Care · Pharmaceuticals · AU
AU$3.26
+1.87% today · -35.3% 1Y
Mayne Pharma Group Limited (ASX: MYX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $189.85M and employs 491 people.
Over the last twelve months the share price has lost 35.3%, trading between 2.04 and 6.50.
Tweenvest scores Mayne Pharma Group Limited across four factors: quality 55/100, value 69/100, growth 36/100. Its strongest factor is value.
MYX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $189.85M
- Revenue (TTM)
- $271.55M
- P/E
- —
- EPS
- -1.05
- Dividend yield
- —
- Beta (5Y)
- 1.00
- 52-week high
- AU$6.50
- 52-week low
- AU$2.04
- Avg volume (3M)
- —
- Shares outstanding
- 81.25M
- Employees
- 491
- Next earnings
- —
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
- ISIN
- AU000000MYX0
- Founded
- 2005
- Listed since
- Jun 29, 2007
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.